Stay updated on Novel Therapeutics for High-Risk AML Clinical Trial
Sign up to get notified when there's something new on the Novel Therapeutics for High-Risk AML Clinical Trial page.

Latest updates to the Novel Therapeutics for High-Risk AML Clinical Trial page
- Check7 days agoChange DetectedA new revision entry (v3.6.2) was added to replace the previous v3.6.0, and the history now includes explicit labels for Contacts/Locations and Study Status in the version history.SummaryDifference0.2%

- Check14 days agoChange DetectedOn 2026-06-17, the record history gained new sections for Contacts/Locations and Study Status, enhancing visibility into who to contact and the trial's current status. The entry from 2026-06-11 was removed.SummaryDifference0.1%

- Check21 days agoChange DetectedThe latest revision adds a 'Check who can join' prompt, a 'Find Contact Information' option, and explicit 'Contacts/Locations' and 'Study Status' sections, and introduces the v3.6.0 revision label dated 2026-06-11 (replacing v3.5.5).SummaryDifference0.3%

- Check28 days agoChange DetectedVersion 2026-06-05 adds Contacts/Locations and Study Status to the record, accompanied by Revision: v3.5.5. This update changes how the study's contact information and current status are presented on the page.SummaryDifference0.2%

- Check35 days agoChange DetectedOn 2026-05-27, the history adds the Study Status and Contacts/Locations sections (version 241) to the record, indicating updated status details and contact information for the trial. A deletion from 2026-05-22 is also reflected in the history.SummaryDifference0.1%

- Check43 days agoChange DetectedThe record history gains entries for Contacts/Locations and Study Status, with corresponding updates on 2026-05-19 to 2026-05-22, indicating where the trial is conducted and the latest status visible in the history.SummaryDifference0.2%

Stay in the know with updates to Novel Therapeutics for High-Risk AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Novel Therapeutics for High-Risk AML Clinical Trial page.